1877-73-2

Usage

Uses

Used in Chemical Synthesis:
3-Nitrophenylacetic acid is used as a synthetic intermediate for the production of various chemical compounds and pharmaceuticals. Its unique structure allows it to be a versatile building block in the synthesis of a wide range of organic molecules.
Used in Research and Development:
3-Nitrophenylacetic acid is utilized in research and development for the study of chemical reactions and the development of new synthetic pathways. Its reactivity and functional groups make it a valuable tool for understanding and optimizing chemical processes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-nitrophenylacetic acid is used as a key intermediate in the synthesis of various drugs and drug candidates. Its presence in the molecular structure can impart specific biological activities, making it an essential component in the development of new therapeutic agents.
Used in Agrochemical Industry:
3-Nitrophenylacetic acid is also employed in the agrochemical industry as a precursor for the synthesis of various agrochemicals, such as herbicides, pesticides, and plant growth regulators. Its role in these applications is crucial for the development of effective and environmentally friendly solutions for agricultural challenges.

InChI:InChI=1/C8H7NO4/c10-8(11)5-6-2-1-3-7(4-6)9(12)13/h1-4H,5H2,(H,10,11)/p-1

Upstream product

• 103-82-2 phenylacetic acid 
• 621-50-1 (3-nitrophenyl)acetonitrile 
• 103566-28-5 6-methyl-4-(3-nitro-benzylidene)-3,4-dihydro-[1,3,5]oxadiazin-2-one 
• 619-23-8 3-Nitrobenzyl chloride 
• 614-48-2 3-nitrochalcone 
• 89894-59-7 1,1,1-trichloro-2-(m-nitrophenyl)ethane 
• 14338-36-4 3-amino phenylacetic acid 
• 108-24-7 acetic anhydride 
• 7697-37-2 nitric acid 
• 7647-01-0 hydrogenchloride 
• 7023-81-6 2-diazo-1-(3-nitrophenyl)ethanone 
• 619-25-0 3-Nitrobenzyl alcohol 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 3041-40-5 2-phenylmalononitrile 

Downstream Products

• 38411-41-5 (3-nitrophenyl)acetyl chloride 
• 14338-36-4 3-amino phenylacetic acid 
• 109572-40-9 (+/-)-(cis-3-amino-cyclohexyl)-acetic acid 
• 5247-25-6 2-(3-nitrophenyl)acetic acid amide 
• 52022-77-2 2-(3-nitrophenyl)ethanol 
• 10268-12-9 methyl 3-nitrophenylacetate 
• 125132-73-2 N-Methyl-2-(3-nitro-phenyl)-N-((1R,2R)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 125073-03-2 N-Methyl-2-(3-nitro-phenyl)-N-((1S,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 125073-03-2 N-Methyl-2-(3-nitro-phenyl)-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 99-08-1 1-methyl-3-nitrobenzene 
• 19829-61-9 3,3'-dinitrobibenzyl 
• 396090-99-6 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione 
• 29955-19-9 1'-(3-nitrophenyl)-2'-(4''-methoxyphenyl)ethan-2'-one 
• 20802-08-8 2-(3-nitrophenyl)-1-phenylethan-1-one 

Relevant academic research and scientific papers

Transaminase-Mediated Amine Borrowing via Shuttle Biocatalysis

Shuttle catalysis has emerged as a useful methodology for the reversible transfer of small functional groups, such as CO and HCN, and goes far beyond transfer hydrogenation chemistry. While a biocatalytic hydrogen-borrowing methodology is well established, the biocatalytic borrowing of alternative functional groups has not yet been realized. Herein, we present a new concept of amine borrowing via biocatalytic shuttle catalysis, which has no counterpart in chemo-shuttle catalysis and allows efficient intermolecular amine shuttling to generate reactive intermediates in situ. By coupling this dynamic exchange with an irreversible downstream step to displace the reaction equilibrium in the forward direction, high conversion to target products can be achieved. We showcase the potential of this amine-borrowing methodology using a biocatalytic equivalent of both the Knorr-pyrrole synthesis and Pictet-Spengler reaction.

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site

The inhibition of glutaminase 1 (GLS1) represents a potential treatment of malignant tumors. Structural analysis led to the design of a novel series of macrocyclic GLS1 allosteric inhibitors. Through extensive structure-activity relationship studies, a promising candidate molecule 13b (LL202) was identified with robust GLS1 inhibitory activity (IC50 = 6 nM) and high GLS1 binding affinity (SPR, Kd = 24 nM; ITC, Kd = 37 nM). The X-ray crystal structure of the 13b-GLS1 complex was resolved, revealing a unique binding mode and providing a novel structural scaffold for GLS1 allosteric inhibitors. Importantly, 13b clearly adjusted the cellular metabolites and induced an increase in the ROS level by blocking glutamine metabolism. Furthermore, 13b exhibited a similar in vivo antitumor activity as CB839. This study adds to the growing body of evidence that macrocyclization provides an alternative and complementary approach for the design of small-molecule inhibitors, with the potential to improve the binding affinity to the targets.

Macrocyclic glutaminase GLS1 inhibitor or pharmaceutically acceptable salt thereof and preparation method and application thereof

The invention relates to the field of biological medicine, in particular to a series of macrocyclic glutaminase inhibitors, a synthesis method and medical application thereof, and particularly relatesto prevention or treatment of glutaminase related diseases. Meanwhile, the inventor performs a series of in-vitro anti-tumor activity evaluation on the synthesized compounds, and particularly, most of the compounds have good inhibitory activity on cancer cells.

Preparation method of phenylacetic acid type compound

The invention discloses a preparation method of a phenylacetic acid type compound. The preparation method of the phenylacetic acid type compound I comprises the following steps that in a solvent and aCO gas phase system, a benzyl halide type compound II, pyridine-2-cobalt carboxylate, palladium acetate and alkaline neutralizers take carbonylation reaction to obtain the phenylacetic acid type compound I. A mixed catalytic system has a synergistic effect; the whole use quantity of catalysts is greatly reduced. When the mixed catalyst is used, a better catalytic effect can be achieved; the characteristics of easily obtaining the catalyst, avoiding the production safety risk of toxic three wastes and the like, reducing the reaction pressure, realizing mild reaction conditions, reducing the production risk, facilitating the production and the like are realized. The formulas are shown in description.

Ruthenium-catalyzed umpolung carboxylation of hydrazones with CO2

The first ruthenium-catalyzed umpolung carboxylation of hydrazones with CO2 to generate important aryl acetic acids is reported. Besides aldehyde hydrazones, a variety of ketone hydrazones, which have not been successfully applied in previous umpolung reactions with other reactive electrophiles, also show high reactivity and selectivity under mild conditions. Moreover, this operationally simple protocol features good functional group tolerance, is readily scalable, and offers easy derivation of important structures, including bioactive felbinac and adiphenine. Computational studies reveal that this umpolung reaction proceeds through the generation of a Ru-nitrenoid followed by concerted [4 + 2] cycloaddition with CO2.

Development of a photoswitchable antagonist of NMDA receptors

N-methyl–Daspartate receptors (NMDARs) are vital for neurological processes such as learning, memory, and synaptic plasticity. As such, small molecules that modulate their function are of interest in the study of numerous neurological diseases. We have synthesized a small library of photoswitches that modulate NMDAR function. The most efficient photoswitch to date is based on a known ligand of the glycine binding site and shows significant subtype selectivity.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Metal-free, catalytic regioselective oxidative conversion of vinylarenes: A mild approach to phenylacetic acid derivatives

A new synthetic approach towards the synthesis of phenylacetic acids from aromatic alkenes has been developed for the first time under mild conditions by employing non-toxic reagents such as molecular iodine and oxone. This metal-free catalytic regioselective oxygenation of vinylarenes proceeds via tandem iodofunctionalization/de-iodination induced rearrangement.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS

Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Palladium-catalyzed silver-mediated α-arylation of acetic acid: A new approach for the α-arylation of carbonyl compounds

A new approach for the α-arylation of acetic acid through Pd-catalyzed silver-mediated direct C-H arylation of acetic acid with aryl iodides was developed. This protocol provided a straightforward method for the synthesis of a diverse set of α-phenylacetic acids. Palladium served on a silver platter: A new approach for the α-arylation of acetic acid through Pd-catalyzed silver-mediated direct C-H arylation of acetic acid with aryl iodides is presented. This protocol provides a straightforward method for the synthesis of a diverse set of α-phenylacetic acids. Deuteration experiments are performed to help elucidate the reaction mechanism.